000			03434nam a22004097a 4500
008			240117s20242024 xxu||||| |||| 00| 0 eng d
022			_a2772-9303
024			_aPMC11308088 [pmc]
024			_aS2772-9303(22)00434-3 [pii]
040			_aOvid MEDLINE(R)
099			_a39132346
245			_aAtherectomy Plus Balloon Angioplasty for Femoropopliteal Disease Compared to Balloon Angioplasty Alone: A Systematic Review and Meta-analysis. [Review]
251			_aJournal of the Society for Cardiovascular Angiography & Interventions. 1(6):100436, 2022 Nov-Dec.
252			_aJ Soc Cardiovasc Angiogr Interv. 1(6):100436, 2022 Nov-Dec.
253			_aJournal of the Society for Cardiovascular Angiography & Interventions
260			_c2022
260			_fFY2022
260			_p2022 Nov-Dec
265			_sepublish
265			_tPubMed-not-MEDLINE
266			_z2024/08/12 06:22
520			_aBackground: The role of atherectomy in treating femoropopliteal disease has been evolving rapidly. However, the clinical efficacy and safety of adjunctive atherectomy to percutaneous balloon angioplasty (BA) (plain balloon and drug-coated BA) remains controversial. We sought to perform a meta-analysis comparing atherectomy plus balloon angioplasty (ABA) versus BA alone in treating femoropopliteal disease.
520			_aConclusions: Data from randomized trials suggest that compared with BA alone, the combination of atherectomy and BA showed no difference in TLR or primary patency. In observational studies, TLR and bailout stenting were reduced in ABA group but there was no difference in primary patency. Further studies are needed to investigate the clinical outcomes of atherectomy combined with BA in femoropopliteal lesions compared with BA alone. Copyright © 2022 The Authors.
520			_aMethods: We searched PubMed, Cochrane Central Register of Clinical Trials, EMBASE, and ClinicalTrials.gov (from inception through January 10, 2022) for studies comparing ABA versus BA for femoropopliteal disease. We used a random-effects model to calculate risk ratio (RR) with 95% CIs. Target lesion revascularization (TLR), primary patency, and bailout stenting were the primary outcomes.
520			_aResults: Nine studies with 699 patients were included (4 randomized and 5 retrospective studies). Compared to BA alone, the ABA group showed a significant decrease in TLR driven by nonrandomized studies (RR 0.59; 95% CI, 0.40-0.85; P = .005) and bailout stenting (RR, 0.32; 95% CI, 0.21-0.48; P < .0001). There was no significant difference in TLR when the analysis was performed including only randomized trials. There was no significant difference in the primary patency between the 2 groups (RR, 1.04; 95% CI, 0.95-1.14; P = .37).
546			_aEnglish
651			_aMedStar Heart & Vascular Institute
651			_aMedStar Washington Hospital Center
656			_aAdvanced Cardiac Catheterization Research Fellowship
657			_aJournal Article
657			_aReview
700			_aAbusnina, Waiel _bMWHC _cAdvanced Cardiac Catheterization Research Fellowship _dMBBCh
700			_aBen-Dor, Itsik _bMHVI
790			_aAbusnina W , Al-Abdouh A , Radaideh Q , Kanmanthareddy A , Shishehbor MH , White CJ , Ben-Dor I , Shammas NW , Nanjundappa A , Lichaa H , Paul TK
856			_uhttps://dx.doi.org/10.1016/j.jscai.2022.100436 _zhttps://dx.doi.org/10.1016/j.jscai.2022.100436
942			_cART _dArticle
999			_c14624 _d14624